Accelus Announces First Surgeries Using FlareHawk ® TiHawk11™ Interbody Fusion System

What To Know

  • This provides surgeons with a 70% increase in footprint as compared to a 10mm-wide interbody device of identical length and allows for two 17mm-wide TiHawk implants to be implanted via a posterior approach to create a 34mm-wide footprint within the disc space.
  • Subsequently, many of our surgeon customers are adapting a posterior approach to many of their fusion cases as all the FlareHawk implants allow the surgeon to directly decompress the nerve root without a compromise in footprint or nerve health, what we term Access without Compromise™.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the first spinal surgeries with the FlareHawk® TiHawk11™ Interbody Fusion System (TiHawk11). TiHawk11 is designed to provide a minimal insertion profile with maximum interbody expansion to increase stability and the likelihood of fusion.

The first TiHawk11 procedure was performed by Dr. Kalman D. Blumberg, a fellowship-trained orthopaedic spine surgeon at Florida Spine Specialists, in Fort Lauderdale, Fla. in May 2022, and since then more than 150 TiHawk11 devices have been implanted to date.

“The titanium-bonded TiHawk11 continues the solid performance of all the Accelus interbody devices produced so far,” Dr. Blumberg said. “This latest version allows a minimal insertion profile compared to its expanded size, which is especially useful for my revision cases requiring a tight dissection. I have found the performance of TiHawk11 to be unparalleled.”

TiHawk11 is part of Accelus’s flagship FlareHawk Interbody Fusion System and features an 11mm-wide insertion profile that expands to 17mm in width and up to 14mm in height within the disc space. This provides surgeons with a 70% increase in footprint as compared to a 10mm-wide interbody device of identical length and allows for two 17mm-wide TiHawk implants to be implanted via a posterior approach to create a 34mm-wide footprint within the disc space.

“Utilizing the TiHawk11 device allows me to maximize expansion in both the medial/lateral and cephalad/caudal planes,” said Dr. Frank P. Cammisa, spine surgeon at Hospital for Special Surgery in New York City. “Its biplanar expansion helps me significantly lower the risk of subsidence, and its ability to conform to the patient’s endplates while allowing for substantial post-packing of graft provides structural support that ultimately increases the chance for fusion.”

TiHawk11 features all the advantages of FlareHawk, now bonded with titanium. TiHawk’s titanium surface technology provides a 0.5 micron-thick layer of commercially pure titanium bonded onto the PEEK through a proprietary process called ion beam assisted deposition. This thin layer of titanium does not alter the favorable properties found with PEEK implants nor does it generate a ghost artifact under fluoroscopic imaging as is common with all-titanium implants, allowing ease of radiographic visualization for TiHawk11 implant placement and fusion assessment.

“We are excited about the key features, advantages and benefits that TiHawk11 brings to surgeons and the results we have seen from these first surgeries,” said Chris Walsh, Accelus CEO and Co-Founder. “Historically the spine market has chased larger footprint implants through adaptive trajectory. Footprint has given rise to interbody approaches such as LLIF, OLIF and ALIF that offer a surgeon the ability to insert larger-footprint implants. However, Accelus’s Adaptive Geometry™ creates medial-lateral and caudal-cranial expansion functionality. Subsequently, many of our surgeon customers are adapting a posterior approach to many of their fusion cases as all the FlareHawk implants allow the surgeon to directly decompress the nerve root without a compromise in footprint or nerve health, what we term Access without Compromise™.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy